{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T05:29:20Z","timestamp":1740634160295,"version":"3.38.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of the study was to explore (1) the synthesis of a novel poly(ethylene glycol) modified lipid (PEG-lipid, PL) containing a chemically active tri-block linker, \u03b5-maleimido lysine (Mal), and its conjugation with salmon calcitonin (sCT), and (2) the biophysical properties and activity of the resulting conjugate, Mal-PL-sCT, relative to the control, 2PEG-Mal-sCT, which comprises sCT conjugated with \u03b1-palmitoyl-N-\u03b5-maleimido-l-lysine at cysteine 1 and cysteine 7, and PEG moieties at lysine 11 and lysine 18 via a conventional stepwise method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The PEG-lipid was obtained by condensing palmitic acid derivative of \u03b5-maleimido lysine with methoxy poly(ethylene glycol) amine. Under reductive conditions, the PEG-lipid readily reacted with sCT to yield the resultant compound, Mal-PL-sCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key findings<\/jats:title><jats:p>Dynamic light scattering analyses suggested that Mal-PL-sCT and 2PEG-Mal-sCT exhibited robust helical structures with a high tendency to aggregate in water. Both compounds were more stable against intestinal degradation than sCT, although Mal-PL-sCT was less stable than 2PEG-Mal-sCT. However, 2PEG-Mal-sCT did not possess hypocalcaemic activity while Mal-PL-sCT retained the hypocalcaemic activity of sCT when it was subcutaneously injected in the rat model. Multiple functional groups may be conjugated to a peptide via a tri-block linker without the risk of obliterating the intrinsic bioactivity of the peptide.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The resultant novel PEG-lipid has a potential role to optimize protein and peptide delivery.<\/jats:p><\/jats:sec>","DOI":"10.1211\/jpp.62.03.0002","type":"journal-article","created":{"date-parts":[[2010,10,14]],"date-time":"2010-10-14T13:05:30Z","timestamp":1287061530000},"page":"296-304","source":"Crossref","is-referenced-by-count":6,"title":["Design, synthesis, characterization and in-vivo activity of a novel salmon calcitonin conjugate containing a novel PEG-lipid moiety"],"prefix":"10.1093","volume":"62","author":[{"given":"Weiqiang","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, National University of Singapore , 18 Science Drive 4, 117543,","place":["Singapore"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee-Yong","family":"Lim","sequence":"additional","affiliation":[{"name":"Pharmacy, School of Biomedical, Biomolecular and Chemical Sciences, University of Western Australia , 35 Stirling Highway, Crawley, Western Australia, 6009,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,3,1]]},"reference":[{"key":"2024103013102018400_cit1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2024103013102018400_cit2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003088-200140070-00005","article-title":"Pegylation: a novel process for modifying pharmacokinetics","volume":"40","author":"Harris","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"2024103013102018400_cit3","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1023\/A:1018929312715","article-title":"Preparation, purification, and characterization of a reversibly lipidized desmopressin with potentiated anti-diuretic activity","volume":"16","author":"Wang","year":"1999","journal-title":"Pharm Res"},{"key":"2024103013102018400_cit4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0168-3659(03)00008-7","article-title":"Reversible lipidization for the oral delivery of salmon calcitonin","volume":"88","author":"Wang","year":"2003","journal-title":"J Control Release"},{"key":"2024103013102018400_cit5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/0014-5793(89)80729-X","article-title":"Fatty acid acylated antibodies against virus suppress its reproduction in cells","volume":"250","author":"Kabanov","year":"1989","journal-title":"FEBS Lett"},{"key":"2024103013102018400_cit6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/bj20031393","article-title":"Acylation of SC4 dodecapeptide increases bactericidal potency against Gram-positive bacteria, including drug-resistant strains","volume":"378","author":"Lockwood","year":"2004","journal-title":"Biochem J"},{"key":"2024103013102018400_cit7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0014-5793(95)00910-2","article-title":"Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides","volume":"371","author":"Ekrami","year":"1995","journal-title":"FEBS Lett"},{"key":"2024103013102018400_cit8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1021\/bc00035a016","article-title":"Fatty acid acylated peroxidase as a model for the study of interactions of hydrophobically-modified proteins with mammalian cells","volume":"6","author":"Slepnev","year":"1995","journal-title":"Bioconjug Chem"},{"key":"2024103013102018400_cit9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-5793(90)81016-H","article-title":"Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes","volume":"268","author":"Klibanov","year":"1990","journal-title":"FEBS Lett"},{"key":"2024103013102018400_cit10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0005-2736(91)90385-L","article-title":"Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target","volume":"1062","author":"Klibanov","year":"1991","journal-title":"Biochim Biophys Acta"},{"key":"2024103013102018400_cit11","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/jps.20150","article-title":"In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation","volume":"93","author":"Ashok","year":"2004","journal-title":"J Pharm Sci"},{"key":"2024103013102018400_cit12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2006.02.018","article-title":"Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux","volume":"315","author":"Dabholkar","year":"2006","journal-title":"Int J Pharm"},{"key":"2024103013102018400_cit13","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1073\/pnas.0931428100","article-title":"Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs","volume":"100","author":"Torchilin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024103013102018400_cit14","doi-asserted-by":"crossref","first-page":"14164","DOI":"10.1073\/pnas.93.24.14164","article-title":"Brain drug delivery of small molecules using immunoliposomes","volume":"93","author":"Huwyler","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024103013102018400_cit15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2337\/diacare.26.2.421","article-title":"Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes","volume":"26","author":"Kipnes","year":"2003","journal-title":"Diabetes Care"},{"key":"2024103013102018400_cit16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.metabol.2003.07.021","article-title":"Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I\/II clinical trial","volume":"53","author":"Clement","year":"2004","journal-title":"Metabolism"},{"key":"2024103013102018400_cit17","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/CIRCULATIONAHA.105.538520","article-title":"Oral human brain natriuretic peptide activates cyclic guanosine 3\u2032,5\u2032-monophosphate and decreases mean arterial pressure","volume":"112","author":"Cataliotti","year":"2005","journal-title":"Circulation"},{"key":"2024103013102018400_cit18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1021\/bc0501000","article-title":"Amphiphilic conjugates of human brain natriuretic peptide designed for oral delivery: in vitro activity screening","volume":"17","author":"Miller","year":"2006","journal-title":"Bioconjug Chem"},{"key":"2024103013102018400_cit19","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1592\/phco.24.11.994.36142","article-title":"Pharmacokinetics of modified oral calcitonin product in healthy volunteers","volume":"24","author":"Chin","year":"2004","journal-title":"Pharmacotherapy"},{"key":"2024103013102018400_cit20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11095-006-9128-9","article-title":"Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity","volume":"24","author":"Cheng","year":"2007","journal-title":"Pharm Res"},{"key":"2024103013102018400_cit21","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1021\/mp8000167","article-title":"Comparison of reversible and nonreversible aqueous-soluble lipidized conjugates of salmon calcitonin","volume":"5","author":"Cheng","year":"2008","journal-title":"Mol Pharm"},{"key":"2024103013102018400_cit22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejps.2009.02.004","article-title":"Lipeo-sCT: a novel reversible lipidized salmon calcitonin derivative, its biophysical properties and hypocalcemic activity","volume":"37","author":"Cheng","year":"2009","journal-title":"Eur J Pharm Sci"},{"key":"2024103013102018400_cit23","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/jps.21524","article-title":"Synthesis, characterization and in vivo activity of salmon calcitonin coconjugated with lipid and polyethylene glycol","volume":"98","author":"Cheng","year":"2009","journal-title":"J Pharm Sci"},{"key":"2024103013102018400_cit24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s002620050387","article-title":"Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs","volume":"44","author":"Cheng","year":"1997","journal-title":"Cancer Immunol Immunother"},{"key":"2024103013102018400_cit25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00223-002-0034-9","article-title":"Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats","volume":"73","author":"Lee","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"2024103013102018400_cit26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10930-005-7837-2","article-title":"Conjugation of multiple copies of polyethylene glycol to hemoglobin facilitated through thiolation: influence on hemoglobin structure and function","volume":"24","author":"Manjula","year":"2005","journal-title":"Protein J"},{"key":"2024103013102018400_cit27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/0003-2697(87)90587-2","article-title":"Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa","volume":"166","author":"Schagger","year":"1987","journal-title":"Anal Biochem"},{"key":"2024103013102018400_cit28","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/jps.2600841120","article-title":"Utility of pharmacodynamic measures for assessing the oral bioavailability of peptides. 1. Administration of recombinant salmon calcitonin in rats","volume":"84","author":"Sinko","year":"1995","journal-title":"J Pharm Sci"},{"volume-title":"Analytical atomic absorption spectroscopy: selected methods","year":"1980","author":"Van Loon","key":"2024103013102018400_cit29"},{"key":"2024103013102018400_cit30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1021\/bc000082g","article-title":"Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C","volume":"12","author":"Bailon","year":"2001","journal-title":"Bioconjug Chem"},{"key":"2024103013102018400_cit31","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jconrel.2006.06.007","article-title":"Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy","volume":"114","author":"Youn","year":"2006","journal-title":"J Control Release"},{"key":"2024103013102018400_cit32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1023\/A:1018698002314","article-title":"Two-dimensional 1H NMR experiments show that the 23-residue magainin antibiotic peptide is an alpha-helix in dodecylphosphocholine micelles, sodium dodecylsulfate micelles, and trifluoroethanol\/water solution","volume":"9","author":"Gesell","year":"1997","journal-title":"J Biomol NMR"},{"key":"2024103013102018400_cit33","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1021\/bi00219a012","article-title":"Two-dimensional NMR and structure determination of salmon calcitonin in methanol","volume":"30","author":"Meadows","year":"1991","journal-title":"Biochemistry"},{"key":"2024103013102018400_cit34","first-page":"287","article-title":"Specificity of trypsin and alpha-chymotrypsin towards neutral substrates","volume":"11","author":"Vajda","year":"1976","journal-title":"Acta Biochim Biophys Acad Sci Hung"},{"key":"2024103013102018400_cit35","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1432-1033.1987.tb10615.x","article-title":"Biologically potent analogues of salmon calcitonin which do not contain an N-terminal disulfide-bridged ring structure","volume":"162","author":"Orlowski","year":"1987","journal-title":"Eur J Biochem"},{"key":"2024103013102018400_cit36","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1210\/endo-126-6-2845","article-title":"A noncyclical analog of salmon calcitonin (N alpha-propionyl Di-Ala1,7,des-Leu19 sCT) retains full potency without inducing anorexia in rats","volume":"126","author":"Yates","year":"1990","journal-title":"Endocrinology"},{"key":"2024103013102018400_cit37","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0006-291X(03)01028-3","article-title":"Solution structure and biological activity of recombinant salmon calcitonin S-sulfonated analog","volume":"306","author":"Wang","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"2024103013102018400_cit38","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1021\/ja00350a064","article-title":"Design of a peptide-hormone - synthesis and characterization of a model peptide with calcitonin-like activity","volume":"105","author":"Moe","year":"1983","journal-title":"J Am Chem Soc"},{"key":"2024103013102018400_cit39","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1021\/bi00356a019","article-title":"Conformational flexibility and biological activity of salmon calcitonin","volume":"25","author":"Epand","year":"1986","journal-title":"Biochemistry"},{"key":"2024103013102018400_cit40","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0026-895X(25)08628-6","article-title":"Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation","volume":"47","author":"Houssami","year":"1995","journal-title":"Mol Pharmacol"},{"key":"2024103013102018400_cit41","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bip.20734","article-title":"Insulin structure and function","volume":"88","author":"Mayer","year":"2007","journal-title":"Biopolymers"},{"key":"2024103013102018400_cit42","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1110\/ps.052004006","article-title":"Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study","volume":"15","author":"Rajan","year":"2006","journal-title":"Protein Sci"},{"key":"2024103013102018400_cit43","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1021\/bc020089t","article-title":"Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo","volume":"14","author":"Leamon","year":"2003","journal-title":"Bioconjug Chem"},{"key":"2024103013102018400_cit44","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1126\/science.1078192","article-title":"Micellar nanocontainers distribute to defined cytoplasmic organelles","volume":"300","author":"Savic","year":"2003","journal-title":"Science"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1211%2Fjpp.62.03.0002","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/62\/3\/296\/60233618\/jpp.62.03.0002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/62\/3\/296\/60233618\/jpp.62.03.0002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T19:06:13Z","timestamp":1740596773000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/62\/3\/296\/6135729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,1]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2010,3,1]]},"published-print":{"date-parts":[[2010,3,1]]}},"URL":"https:\/\/doi.org\/10.1211\/jpp.62.03.0002","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"type":"print","value":"0022-3573"},{"type":"electronic","value":"2042-7158"}],"subject":[],"published-other":{"date-parts":[[2010,3]]},"published":{"date-parts":[[2010,3,1]]}}}